BioCentury
ARTICLE | Company News

Orega Biotech, Innate Pharma deal

February 1, 2016 8:00 AM UTC

Orega granted Innate exclusive, worldwide rights to develop and commercialize a program of undisclosed antibodies against ectonucleoside triphosphate diphosphohydrolase 1 ( ENTPD1; CD39) that are in...